Norcantharidin (NCTD) is a promising antitumor drug with low toxicity. It was reported to be able to regulate immunity, but the mechanism is not yet clear. Here 
Norcantharidin, the demethylated analogue of CTD, 11 has strong anti-oxidant, antitumor, and antimetastatic activity, 12 but much less toxicity than CTD in the clinical application. 13 Published studies have reported that NCTD could significantly induce apoptosis and inhibit proliferation of tumor cells through different signaling pathways. 14, 15 Mechanistic studies showed that NCTD-induced apoptosis is mediated by regulating some transcription factors, including nuclear factor-jB, activator protein-1, Forkhead box O, and signal transducer and activator of transcription, which can independently or collaboratively regulate the expression of apoptotic or anti-apoptotic genes. 15, 16 Norcantharidin was reported to have an effect on immune regulation, 17 but its effect on Tregs is not yet clear.
In our previous research, a cancer cell vaccine was developed by anchoring streptavidin-tagged GM-CSF on the surface of prostate cancer cells. 18 We found that the vaccine could enhance antitumor immune responses, but the number of Tregs also increased in the vaccine-treated mice at the same time. The present study was undertaken to evaluate the effect of NCTD on apoptosis and proliferation of Tregs in vitro and explore the underlying mechanism. A mouse prostate cancer model was used to evaluate the efficacy of a combination therapy with NCTD and cancer cell vaccine.
| MATERIALS AND METHODS

| Materials
Tumor tissues were obtained from 20 PCa patients and normal tissues were selected from 10 patients who received pathological biopsy of benign disease in Nanfang Hospital (Guangzhou, China).
None of these patients had received immune-regulating drugs or radiation therapy before surgery. The study was approved by the ethics committee and informed consent was obtained from all patients. Norcantharidin, CCK-8, and DAPI reagents were purchased from Sigma (St. Louis, MO, USA). Streptavidin-tagged mouse GM-CSF (SA-mGM-CSF) fusion protein was prepared by our laboratory.
Western blotting antibodies against p-ERK1/2, p-Akt, ERK1/2, Akt, Bcl-2, FOXO1, FasL, and GAPDH were purchased from Abcam (Cambridge, UK). Phycoerythrin-labeled anti-mGM-CSF, FITC-labeled anti-mCD11c, PE-labeled anti-mCD80, FITC-labeled anti-mCD4, FITC-labeled anti-mCD8 and PerCP-Cyanine 5.5-labeled anti-mFoxP3
antibodies were purchased from eBioscience (San Diego, CA, USA).
C57BL/6 male mice (6-8 weeks old) were purchased from the experimental animal center of Southern Medical University (Guangzhou, China). All animal studies were undertaken in accordance with the Southern Medical University guidelines for experimental animals.
| Cell sorting
To obtain Tcons, the spleens were collected from C57/BL6 mice, then ground and isolated by lymphocyte separation liquid (Solarbio).
Regulatory T cells were isolated from Tcons according to the procedure of the CD4 + CD25 + Regulatory T Cells Isolation Kit (Miltenyi Biotec, Germany), and the rest of the cells were considered as nonTregs. Their purity and the ratio of viability were assessed by flow cytometry (Becton Dickinson, San Jose, CA, USA).
| Cell culture and stimulation
The mouse prostate cancer cell line (RM-1) was purchased from ATCC (Manassas, VA, USA). The cells were maintained in RPMI-1640 supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/L streptomycin at 37°C in a humidified atmosphere of 5% CO 2 . The Tcons, Tregs, and non-Tregs were cultured in the presence of 1 lg/mL soluble anti-mouse CD3 and anti-mouse CD28 (1:1)
antibody.
| Cell proliferation assay
The Tcons, Tregs, and non-Tregs were inoculated into 96-well plates 
| Apoptosis assay
The Tcons, Tregs, and non-Tregs were cultured in 24-well 
| Western blot analysis
Regulatory T cells were cultured and treated with NCTD as previously described. Cells were collected and dissolved in RIPA buffer. 
| Vaccine preparation
The 
| Statistics
The results show the most typical of three independent experiments.
Data are shown as mean AE SD and were analyzed with IBM SPSS version 20.0. Differences between groups were analyzed using the repeated measures or one-way ANOVA, or t test, with significant difference defined as P < .05.
| RESULTS
| Tumor-infiltrating Tregs in human prostate cancer
Immunohistochemistry was carried out to detect the infiltration of Tregs in human prostate cancer tissue. The results indicated that the quantity of Tregs in tumor tissues was significantly higher than that in normal tissues (P < .05; Figure 1A ).
| Effect of NCTD on proliferation and apoptosis of Tregs
Magnetic cell sorting collected a high purity of Tregs from the spleens of mice (>90%; Figure 1B In addition, NCTD dramatically induced the apoptosis of Tregs (P < .05; Figure 2 ). All effects were in a dose-and time-dependent manner.
| Norcantharidin downregulated p-AKT and activated FOXO1
Western blot analysis was used to explore the associated mechanism regarding apoptosis of Tregs. The results showed that NCTD downregulated p-Akt, whereas the total Akt protein level unchanged. Treatment with NCTD increased the levels of FOXO1 and FasL protein and decreased the level of Bcl2 protein (P < .05; Figure 3A ), but there is no obvious change in the level of ERK or p-ERK. Real-time PCR analysis showed that mRNA levels of Fas, FasL, FOXO3a, FOXO4, and FOXO1 were significantly upregulated in NCTD-treated Tregs (P < .05; Figure 3B ). It is suggested that NCTD might induce apoptosis through inhibiting AKT and hence activating the FOXO1-FasL axis.
| Antitumor efficacy of vaccine therapy combined with NCTD
Flow cytometry revealed that SA-mGM-CSF could be efficiently anchored on the surface of biotinylated RM-1 cells ( Figure 4A ). The RM-1 s.c. mouse model was used to evaluate the antitumor efficacy of the vaccine combined with NCTD. Our results showed that the RM-1 cell vaccine modestly inhibited tumor growth. The addition of NCTD to the vaccine treatment was more effective in restraining tumor growth than vaccine alone (P < .05; Figure 4B ). These results suggest that NCTD could promote the antitumor immunity of tumor cell vaccines.
| Flow cytometry analysis of DCs in blood
To evaluate the effect of the GM-CSF surface-modified tumor cell vaccine on mature DC cells, cells were collected from the blood and analyzed by flow cytometry. The results showed that mature DCs were distinctly increased after treatment with GM-CSF surface-modified vaccine. Treatment with NCTD alone had no significant effect on DC maturation (P < .05; Figure 5A ).
| Norcantharidin therapy decreased Treg populations in vivo
Flow cytometry was used to investigate the quantity of Tregs in blood. As anticipated, the frequency of Tregs was increased in the Vaccine group and decreased in the NCTD group compared to the PBS group. Importantly, the frequency was much lower in the Vaccine + NCTD group compared to the Vaccine group (P < .05; Figure 5B ). The proportions of Tregs in tumor tissues were detected using immunofluorescence. The results showed that more Tregs were infiltrated into the tumor tissues after the vaccine therapy. In the combination group, the number of Tregs was less than that in the Vaccine group (P < .05; Figure 5C ). These results indicated that NCTD could decrease the number of infiltrating Tregs in vaccine treatment.
| Flow cytometry analysis of CD4 + and CD8 + T lymphocytes in blood after vaccine treatment
The rates of CD4 + and CD8 + T lymphocytes in peripheral blood of mice were analyzed by flow cytometry. Results showed that the proportions of CD4 + and CD8 + T cells were increased after treatment with vaccine or NCTD (P < .05; Figure 6A ). The proportions of CD4 + F I G U R E 5 Proportion of mature dendritic cells (DCs) and regulatory T cells (Tregs) in mice after combination therapy with norcantharidin (NCTD) and vaccine. A, To detect the mature DCs, blood samples were collected from each treatment group on day 30 after tumor cell injection. Cells were stained with FITC-labeled anti-mCD11c and phycoerythrin (PE)-labeled anti-mCD80 antibodies, and measured by flow cytometry. B, Blood samples were collected from mice on day 30 after tumor cell injection and stained with FITC-labeled anti-mCD4 and Pecy5.5-labeled anti-mFoxp3 antibodies. C, Tumor tissues were collected from each group. Tregs were detected by immunofluorescence (red) (magnification, 9200). All experiments were repeated at least three times. *P < .05 vs PBS; 31 However, PI3K/AKT could negatively regulate FOXO1 and lead to apoptosis. 32 Previous observations suggested that FOXO1 is a pivotal regulator of Treg cell function, 33 and negatively regulates Treg differentiation. 34 In this study, we ana- 
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